JHEP Reports

Article	Citations
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper	314
Non-alcoholic fatty liver disease: A patient guideline	113
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic	105
NAFLD and liver transplantation: Disease burden, current management and future challenges	94
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial	87
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors	82
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment	82
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma	80
Lipid alterations in chronic liver disease and liver cancer	78
New targets for NAFLD	77
Organoids to model liver disease	74
Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction	66
Where does TIPS fit in the management of patients with cirrhosis?	61
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma	61
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy	60
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity	60
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease	55
NAFLD and MAFLD as emerging causes of HCC: A populational study	52
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B	51
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study	51
Novel vectors and approaches for gene therapy in liver diseases	51
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area	49
The liver matrisome – looking beyond collagens	49
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg	47
Gut dysbiosis as a driver in alcohol-induced liver injury	45

New frontiers in liver resection for hepatocellular carcinoma	45
Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials	45
Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD	42
Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy	38
Nuclear deformation mediates liver cell mechanosensing in cirrhosis	36
Understanding the cellular interactome of non-alcoholic fatty liver disease	36
The ALBI score: From liver function in patients with HCC to a general measure of liver function	35
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases	35
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease	34
Assessing the impact of COVID-19 on liver cancer management (CERO-19)	34
De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA	34
Combined alcoholic and non-alcoholic steatohepatitis	34
Real-world experience with obeticholic acid in patients with primary biliary cholangitis	33
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation	33
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis	32
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis	32
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the past	31
Cell of origin in biliary tract cancers and clinical implications	31
Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension	31
New insights on the role of vascular endothelial growth factor in biliary pathophysiology	31
Approach to the patient with acute severe autoimmune hepatitis	30
Evaluation of liver tumour response by imaging	30
Evaluating causality of cellular senescence in non-alcoholic fatty liver disease	29
Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation	29
Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD	29
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	29
Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS	29
The role of cGAS-STING signalling in liver diseases	29
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis	28
A human liver chimeric mouse model for non-alcoholic fatty liver disease	28
Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis	27
Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review	27
Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D	27
European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?	26
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice	26
Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction	26
Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions	25
The neurogliovascular unit in hepatic encephalopathy	25
Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis	25
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease	25
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2	25
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets	24
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation	24
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	24
A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients	24
NASH-related increases in plasma bile acid levels depend on insulin resistance	24
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes	24
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study	23
Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA	23
Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities	23

Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma	23
Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model	23
Stratification of patients in NASH clinical trials: A pitfall for trial success	22
Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort	22
Influence of surgical approach and quality of resection on the probability of cure for early-stage HCC occurring in cirrhosis	22
New insights into the pathophysiology and clinical care of rare primary liver cancers	22
Adding the oxygen carrier M101 to a cold-storage solution could be an alternative to HOPE for liver graft preservation	22
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance	21
Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents	21
Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities	21
Embedding assessment of liver fibrosis into routine diabetic review in primary care	21
Using cell-free DNA for HCC surveillance and prognosis	21
Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma	20
Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease	20
Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy	20
ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis	20
Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis	20
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication	20
Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis	19
Features and outcome of AIH patients without elevation of IgG	19
TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload	19
Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC	18
From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?	18
Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis	18
Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease	18
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	18
Treating hepatitis D with bulevirtide – Real-world experience from 114 patients	18
Novel role of macrophage TXNIP-mediated CYLD–NRF2–OASL1 axis in stress-induced liver inflammation and cell death	18
Elevated plasma ICAM1 levels predict 28-day mortality in cirrhotic patients with COVID-19 or bacterial sepsis	18
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma	18
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination	18
Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event	18
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care	17
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	17
Case-finding strategies in non-alcoholic fatty liver disease	17
Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis	17
Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines	17
Are the new genetic tools for diagnosis of Wilson disease helpful in clinical practice?	17
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis	17
Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections	17
XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression	17
TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection	16
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B	16
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection	16
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity	16
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure	16
Non-invasive biomarkers of Fontan-associated liver disease	16
Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators	16
Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma	15
Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county	15
Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure	15
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis	15
Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis	15
Hepatic microbiome in healthy lean and obese humans	15
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials	15
Hepatopulmonary syndrome	15
Epigenetics of alcohol-related liver diseases	15
Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank	15
Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor	15
Management of splanchnic vein thrombosis	15
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates	15
Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2 mouse	15
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	14
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice	14
Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure	14
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	14
Abnormal liver tests in patients with SARS-CoV-2 or influenza – prognostic similarities and temporal disparities	14
Hepatic sarcoidosis: Clinical characteristics and outcome	14
Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis	14
Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults	13
Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade	13
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	13
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD	13
Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis	13
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis	13
ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis	13
Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination	13
Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis	12
Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy	12
Cellular origins of regenerating liver and hepatocellular carcinoma	12

Evidence for long-term association of virion-delivered HBV core protein with cccDNA independently of viral protein production	12
Ablation of liver Fxr results in an increased colonic mucus barrier in mice	12
CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson’s disease	11
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction	11
Defatting strategies in the current era of liver steatosis	11
Emerging roles of circular RNAs in liver cancer	11
Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV	11
Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score	11
IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer	11
Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study	11
Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness	11
A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation	11
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	11
Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction	10
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis	10
Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome	10
International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria	10
Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection	10
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals	10
Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis	10
Hepatocyte mARC1 promotes fatty liver disease	10
Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Pi∗MZ genotype	10
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	10
Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C	10
Abnormal brain oxygen homeostasis in an animal model of liver disease	10
Higher subcutaneous adipose tissue radiodensity is associated with increased mortality in patients with cirrhosis	10
Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma	10
Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas	10
Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system	10
Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada	10
Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B	10
Saturated fatty acid-enriched small extracellular vesicles mediate a crosstalk inducing liver inflammation and hepatocyte insulin resistance	10
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p	9
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF	9
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis	9
(13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle	9
Spleen volume-based non-invasive tool for predicting hepatic decompensation in people with compensated cirrhosis (CHESS1701)	9
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial	9
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	9
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	9
Use of albumin infusion for cirrhosis-related complications: An international position statement	9
Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS	9
A small animal model of chronic hepatitis E infection using immunocompromised rats	9